Holen Sie sich die Stockscreener-App
2.19
1.35%
-0.03
Handel nachbörslich:
2.20
0.01
+0.46%
Schlusskurs vom Vortag:
$2.22
Offen:
$2.24
24-Stunden-Volumen:
1.08M
Relative Volume:
0.60
Marktkapitalisierung:
$212.24M
Einnahmen:
$20.76M
Nettoeinkommen (Verlust:
$-132.49M
KGV:
-0.8202
EPS:
-2.67
Netto-Cashflow:
$-108.55M
1W Leistung:
+14.66%
1M Leistung:
-13.78%
6M Leistung:
+28.07%
1J Leistung:
-42.97%
1-Tages-Spanne:
$2.12
$2.27
1-Wochen-Bereich:
$1.87
$2.33
52-Wochen-Spanne:
$1.085
$4.07
C 4 Therapeutics Inc Stock (CCCC) Company Profile
Firmenname
C 4 Therapeutics Inc
Sektor
Branche
Telefon
(617) 231-0700
Adresse
490 ARSENAL WAY, WATERTOWN
Vergleichen Sie CCCC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CCCC
C 4 Therapeutics Inc
|
2.19 | 215.15M | 20.76M | -132.49M | -108.55M | -2.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
C 4 Therapeutics Inc Stock (CCCC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-02 | Eingeleitet | TD Cowen | Buy |
| 2025-09-17 | Eingeleitet | Barclays | Overweight |
| 2025-09-15 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2025-09-04 | Eingeleitet | Guggenheim | Buy |
| 2024-12-19 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-11-18 | Eingeleitet | Stephens | Equal-Weight |
| 2024-01-29 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2023-12-13 | Hochstufung | Stifel | Hold → Buy |
| 2023-02-24 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2023-02-24 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2022-11-04 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-10-11 | Eingeleitet | Morgan Stanley | Underweight |
| 2022-04-28 | Eingeleitet | Credit Suisse | Underperform |
| 2022-04-11 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-03-10 | Eingeleitet | JP Morgan | Overweight |
| 2022-02-11 | Fortgesetzt | BMO Capital Markets | Outperform |
| 2022-02-10 | Eingeleitet | Wells Fargo | Equal Weight |
| 2021-11-23 | Eingeleitet | BofA Securities | Buy |
| 2021-10-14 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2021-09-30 | Eingeleitet | Stifel | Hold |
| 2021-06-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-03-31 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-10-28 | Eingeleitet | UBS | Buy |
| 2020-10-27 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-10-27 | Eingeleitet | Jefferies | Buy |
Alle ansehen
C 4 Therapeutics Inc Aktie (CCCC) Neueste Nachrichten
Is C4 Therapeutics Inc. stock trading at a premium valuationWeekly Trend Recap & Smart Swing Trading Techniques - ulpravda.ru
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PharmiWeb.com
Is C4 Therapeutics Inc. stock in correction or buying zoneJuly 2025 Big Picture & Safe Swing Trade Setups - ulpravda.ru
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
Is C4 Therapeutics Inc. stock oversold or undervaluedMarket Growth Review & Accurate Entry/Exit Alerts - ulpravda.ru
Brookline Capital Management Estimates C4 Therapeutics FY2030 Earnings - MarketBeat
Akebia Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
Fate Therapeutics reports new employee inducement awards under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Intellia Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
Karyopharm Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Business Wire
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)December 31, 2025 - BioSpace
Sarepta Therapeutics announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
Is C4 Therapeutics (CCCC) one of the best biotech penny stocks to buy according to analysts? - MSN
Is C4 Therapeutics (CCCC) One of the Best Biotech Penny Stocks to Buy According to Analysts? - Insider Monkey
Abeona Therapeutics® announces new employee inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Caledonian Record
C4 Therapeutics, Inc. (NASDAQ:CCCC) Sees Significant Growth in Short Interest - MarketBeat
With 43% stake, C4 Therapeutics, Inc. (NASDAQ:CCCC) seems to have captured institutional investors' interest - Yahoo Finance
C4 Therapeutics (CCCC) Loses -26.18% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - MSN
Zevra Therapeutics Executes Distribution Agreement to - GlobeNewswire
Can C4 Therapeutics Inc. stock resist sector downturnsMarket Sentiment Report & Analysts Are Raving About These Shares - bollywoodhelpline.com
How C4 Therapeutics Inc. stock performs in weak economyWall Street Watch & Fast Exit and Entry Strategy Plans - Улправда
Energy Moves: How C4 Therapeutics Inc stock compares to growth peersWeekly Profit Analysis & Real-Time Stock Entry Alerts - moha.gov.vn
Can C4 Therapeutics Inc. stock rebound after recent weaknessJuly 2025 Big Picture & Real-Time Buy Zone Alerts - Улправда
EV Market: Will C4 Therapeutics Inc. stock remain a Wall Street favoriteWeekly Investment Summary & Weekly Stock Breakout Alerts - Улправда
Exit Recap: Why C4 Therapeutics Inc. stock remains a top recommendationJuly 2025 Pullbacks & Real-Time Buy Zone Alerts - Улправда
Will C4 Therapeutics Inc. stock attract more institutional investors2025 Sector Review & Technical Pattern Based Signals - DonanımHaber
Layoff Watch: How C4 Therapeutics Inc. stock performs in weak economy2025 Trading Volume Trends & Safe Capital Investment Plans - Улправда
Will C4 Therapeutics Inc. stock remain a Wall Street favoriteJuly 2025 Market Mood & Risk Controlled Stock Alerts - Улправда
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
How C4 Therapeutics Inc. stock performs during Fed tightening cycles2025 Risk Factors & Expert Approved Momentum Trade Ideas - Улправда
Why C4 Therapeutics Inc. stock remains a top recommendationDip Buying & Weekly High Return Stock Forecasts - Улправда
Barclays Maintains C4 Therapeutics (CCCC) Overweight Recommendation - Nasdaq
Barclays Lowers Price Target for C4 Therapeutics (CCCC) Despite Maintaining Overweight Rating | CCCC Stock News - GuruFocus
C4 Therapeutics Target of Unusually High Options Trading (NASDAQ:CCCC) - MarketBeat
Insufficient Growth At C4 Therapeutics, Inc. (NASDAQ:CCCC) Hampers Share Price - simplywall.st
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - PharmiWeb.com
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Yahoo Finance
C4 Therapeutics, Inc. (NASDAQ:CCCC) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)December 11, 2025 - BioSpace
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Globe and Mail
Travere Therapeutics (NASDAQ: TVTX) issues 20,300 new-hire RSUs vesting over four years - Stock Titan
BBOT Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Finanzdaten der C 4 Therapeutics Inc-Aktie (CCCC)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.80%
4.56%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):